Abbott's Alliance With Insulet To Fortify Diabetic Care Unit

 | Feb 23, 2020 09:08PM ET

Abbott's (NYSE:ABT) recent alliance with insulin management system maker, Insulet Corporation (NASDAQ:PODD) , is expected to fortify the company’s Diabetes Care business. The agreement aims at integrating Abbott’s continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon Automated Insulin Delivery (AID) System, in order to provide improved insulin delivery.

This combined system is claimed to be the first with a fully-disposable wearable sensor and pump. However, financial terms of the deal remain undisclosed.

Is the Integration Strategic?

Under the integrated platform, the Omnipod Horizon System will provide a new feature combining Insulet’s tubeless insulin delivery Pod and Abbott's next-generation FreeStyle Libre sensor — the FreeStyle Libre 2 system.